Carl Dambkowski, M.D., has served as Chief Medical Officer since September 2022. He also serves on the Board of Oruka Therapeutics. Prior to joining Apogee, Dr. Dambkowski served as a strategic and clinical leader for a variety of companies. He was part of the core teams that brought TRUSELTIQ (infigratinib) and NULIBRY (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences. He also served as an Associate at McKinsey & Company, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities and co-founded Novonate, Inc., a private medical device company focused on building life-saving devices for neonates. Dr. Dambkowski trained as a physician at Stanford University, where he received his M.D. with a concentration in bioengineering. He also holds an M.A. from Columbia University and a B.A. from Stanford University. The father of two and avid runner, he has run a sub 6-minute mile while pushing his daughter in a stroller.